MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- DR. REDDYS LAB
DR. REDDYS LAB Share Price (REDY)
Here is the latest stock price and chart of Dr. Reddys. For more details, see the Dr. Reddys company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Apr 1, 2020 (Close) | ||
|---|---|---|---|
| Price (Rs)3,096.20 | Open (Rs) 3,180.00 | High (Rs) 3,180.00 | Low (Rs) 3,068.70 |
| % Change-0.67 | Volume 16,061 | Value (Rs) 49,750,559 | 52-Week H/L 3,363.00 / 2,352.00 |
| Live NSE Quotes | Apr 1, 2020 (Close) | ||
|---|---|---|---|
| Price (Rs)3,095.00 | Open (Rs) 3,119.95 | High (Rs) 3,144.00 | Low (Rs) 3,066.00 |
| % Change-0.83 | Volume 711,048 | Value (Rs) 2,202,279,587 | 52-Week H/L 3,364.95 / 2,351.20 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 98.91 | P/E Ratio (x) 31.30 | Market Cap (Rs m) 513,071.30 | P/BV (x) 3.66 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
DR. REDDYS LAB Share Price Today:
DR. REDDYS LAB last traded price was down 0.7% to Rs 3,096.2 on the BSE. On the NSE, DR. REDDYS LAB last traded price was down 0.8% to Rs 3,095.0. The total volume of shares traded was 0.7 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 1.5%. And the benchmark S&P BSE SENSEX was at 28,265.3 (down 4.1%).
Over the last 30 days, the DR. REDDYS LAB share price is up 6.9%. And over the last one year, DR. REDDYS LAB share price is up 10.9%.
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- BSE A Group Gainers Today
- NSE Above Rs 20 Gainers Today
- BSE Above Rs 20 Gainers Today
- BSE Sensex Gainers Today
- BSE Small Cap Gainers Today
- BSE 500 Gainers Today
- BSE A Group Losers Today
- Most Active Stocks Rs 1 to 2
- NSE Above Rs 20 Losers Today
- ANALYSE:
- TCS
- HDFC BANK
- ITC LIMITED
- ONGC
- HINDUSTAN UNILEVER
- SBI
Today's Market
Sensex Crashes 1,203 Points; IT and Banking Stocks Witness Selling(Closing)
Indian share markets extended losses in the first trading session of FY21, as the number of coronavirus cases in the country continued to rise.
Related Views On News
DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)
Feb 4, 2019 | Updated on Feb 4, 2019For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.
DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)
Jul 27, 2018 | Updated on Jul 27, 2018For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.
More Views on NewsMost Popular
If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It. (Profit Hunter)
Mar 19, 2020Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.
Sorry Warren Buffett, I'm Following This Man Instead of You in 2020 (The 5 Minute Wrapup)
Mar 30, 2020This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...
Why India Will Be the Biggest Winner in a Post-Coronavirus World (The 5 Minute Wrapup)
Mar 19, 2020The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...
A Big Trading Opportunity is Coming Your Way Soon (Fast Profits Daily)
Mar 25, 2020I see a big opportunity to make fast profits on the horizon.
Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock (Profit Hunter)
Mar 24, 2020Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.
MoreOUR TOP 5 IDEAS
- How to Trade the Coronavirus Crash - Download this FREE Report Now
- How to Profit Even During These Times of Crisis: Vijay Bhambwani Reveals his Strategy...
- The Best Stocks For 2020 - How to Spot Multibagger Ideas. FREE Sign up!
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- Find Out Our Top 7 Bluechips for 2020 Virtually FREE. Click Here Now!
TRACK DR. REDDYS LAB
- Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DR. REDDYS LAB
DR. REDDYS LAB - ELDER PHARMA COMPARISON
COMPARE DR. REDDYS LAB WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.